Skip Navigation LinksHome > Published Ahead-of-Print > Pharmacokinetic and Safety Profiles of Repeated-dose Prophyl...
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0000000000000218
Clinical and Laboratory Observations: PDF Only

Pharmacokinetic and Safety Profiles of Repeated-dose Prophylactic Micafungin in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplantation.

Albano, Edythe MD; Azie, Nkechi MD; Roy, Mike PhD; Townsend, Robert PhD; Arrieta, Antonio MD

Published Ahead-of-Print
Collapse Box

Abstract

Micafungin is a potent echinocandin antifungal that can be used for both prophylaxis and treatment of Candida infections. This open-label study assessed the pharmacokinetics and safety profile of prophylactic micafungin in children and adolescents (aged 4 mo to 16 y) undergoing hematopoietic stem cell transplantation. Patients received once-daily doses of either 1 or 1.5 mg/kg micafungin, based on their body weight, for 10 to 14 days. In total, 40 patients received micafungin. Area under the plasma micafungin concentration-time curve was highest in patients aged 6 to 11 years in the 1.5 mg/kg treatment group. Peak plasma micafungin concentration displayed no age-related differences, but was higher in the 1.5 mg/kg versus the 1 mg/kg group. Clearance at steady state by weight and volume of distribution by weight were considerably higher in patients aged 4 months to 5 years. Results from this study show that age and body weight affect micafungin pharmacokinetics in pediatric patients undergoing hematopoietic stem cell transplantation.

(C) 2014 by Lippincott Williams & Wilkins.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.